Eli Lilly’s tirzepatide achieves 15.7% weight loss in adult patients
Eli Lilly has announced that tirzepatide (10mg and 15mg) achieved significant and superior weight loss compared to a placebo over 72 weeks of treatment. This data follows results from the SURMOUNT-2 trial, which met all co-primary and secondary endpoints.
The results showed that those taking tirzepatide lost up to 15.7% (34.4lb or 15.6kg) of body weight for the efficacy estimand. On a 10mg dose patients lost an average 13.4%, while 15mg dose patients demonstrated a loss of 15.7%.
Furthermore, 81.6% (10mg) and 86.4% (15mg) of patients taking the drug experienced at least 5% body weight reduction, which was the trial’s other co-primary endpoint, compared to only 30.5% of the placebo group.
The drug also met all secondary endpoints in the trial and the safety profile remained consistent to previously reported SURMOUNT and SURPASS trials. These secondary endpoints included reduction in A1C and other cardiometabolic parameters; 41.4% (10mg) and 51.8% (15mg) of patients taking the drug achieved at least 15% body weight reduction compared to only 2.6% of those in the placebo group.
Jeff Emmick MD PhD, senior vice president of product development at Eli Lilly, commented: “Obesity is a difficult-to-manage disease, and it’s even more difficult for people living with type 2 diabetes. The degree of mean weight reduction seen in SURMOUNT-2 has not been previously achieved in phase 3 trials for obesity or overweight and type 2 diabetes.”
Pharmaceutical Industry news, analysis and insights